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In 1939, René Dubos discovered gramicidin—the first clinically tested 
antibiotic agent. This discovery helped revive the stalled interest in penicillin 
and launched the era of antibiotics.
The notion that microbes can inhibit 
other microbes dates back to the late 
1800s, when Louis Pasteur showed that 
anthrax cultures were robbed of their 
virulence when exposed to aerobic mi-
crobes. Dubos based his early experi-
ments on this principle of “antibiosis” 
and “the supremely simple working 
hypothesis that soil as a self-purifying 
environment could supply an agent to 
destroy disease-causing bacteria” (1).
Digging in the dirt
In 1927—two years before Alexander 
Fleming discovered penicillin—Oswald 
Avery recruited Dubos, a young soil 
microbiologist, to The Rockefeller In-
stitute. Avery challenged Dubos to find 
a soil microbe that could destroy the 
durable polysaccharide capsule of type 
III pneumococcal bacteria—a deadly 
bacterial strain that was resistant to 
neutralization by type-specific antiserum 
and was thus impervious to the serum 
therapy then used to treat patients with 
pneumococcal pneumonia.
Dubos accepted Avery’s challenge 
and set out in search of capsule-killing 
microbes. His approach was simple. Du-
bos put soil samples on a high-carb diet 
of purified type III pneumococcal poly-
saccharide and, over time, coaxed out a 
capsule-devouring bacterium. From this 
new bacterium, Dubos isolated the 
capsule-degrading S III enzyme.
The S III enzyme, which worked by 
stripping the bacteria of their sugary coats 
and rendering them vulnerable to attack 
by phagocytic cells, protected mice against 
infections with type III pneumococci. 
This discovery was first announced in 
Science (2), but was published in detail in 
two papers in The Journal of Experimental 
Medicine (3, 4). Despite its promise in an-
imal models, the S III enzyme could not 
be used to treat patients, as the enzyme 
was difficult to purify and detoxify and 
worked poorly in patients with immune 
systems weakened by disease.
Although Dubos later used rabbits to 
raise type III–specific antibodies that 
ameliorated disease in patients with type 
III pneumonia (5), the use of serum 
therapy became passé by 1940 with the 
development of antibacterial sulfa drugs.
A kinder, gentler drug
But Dubos forged ahead, turning back 
to the soil in search of new agents to 
combat other bacterial infections. 
Among such infections were those 
caused by Gram-positive bacteria, such 
as hemolytic streptococci, identified in 
1931 as the causative agent of rheu-
matic fever—a disease that afflicted 
both Dubos and his first wife (1).
Dubos’s tactics remained largely the 
same, except he fed the soil a more com-
plex diet of whole bacterial particles. Soil 
reared for two years on a mixture of 
staphylococci, pneumococci, and hemo-
lytic streptococci yielded a spore-forming 
bacillus (Bacillus brevis) that could attack 
and kill most Gram-positive bacteria. 
These findings were also published in The 
Journal of Experimental Medicine (6, 7).
Dubos turned to biochemist Rollin 
Hotchkiss for help in defining the 
chemical nature of the antibacterial sub-
stance produced by B. brevis. The duo’s 
analysis revealed that the active substance 
(dubbed tyrothricin) contained two dis-
tinct polypeptides. One (referred to by 
Hotchkiss as the “roughneck” tyroci-
dine) was a lysin that attacked the mem-
branes of both Gram-positive and 
Gram–negative bacteria. The second 
was gramicidin (“the gentle protector”), 
a subtler, bacteriostatic agent that selec-
tively inhibited the growth of Gram-
positive bacteria (8, 9).
Reviving penicillin
“We had high hopes,” recalled Hotchkiss 
in 1990, “that we had [found] a power-
ful new curative and preventative 
medicine” (1). But although a single 
intraperitoneal injection of gramicidin 
protected mice against fatal bacterial 
infections, the compound was toxic 
when administered intravenously and 
thus could not be used to treat systemic 
infections. Topical gramicidin, how-
ever, proved highly effective and was 
used during World War II to treat 
wounds and ulcers. Indeed, gramicidin 
is still an ingredient in some modern-
day topical antibiotics.
Although ultimately of limited prac-
tical use, gramicidin was the first natural 
antibiotic discovered through a deliber-
ate, systematic search for antibacterial 
compounds. And without it, penicillin 
might have been left to languish. How-
ard Florey (Oxford University) credited 
Dubos for reviving his research on peni-
cillin, which was shelved for nearly a 
decade after its uncelebrated discovery 
by Fleming in 1929 (10).
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René Dubos in 1941.
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